Becton Dickinson stock faces analyst target cuts amid medtech pivot and undervaluation debate

Becton Dickinson, the NYSE-listed medical technology leader behind the BDX stock, continues to draw investor scrutiny as it navigates a strategic transformation into a pure-play medtech company. Shares listed on the NYSE have faced headwinds, declining 18.8% year to date and 9.6% over the past year, with the stock last closing around US$158 on the NYSE. This pullback comes despite a recent Q1 earnings beat, where the company reported adjusted EPS of $2.91 against expectations of $2.81 and revenue of $5.25 billion versus $5.15 billion anticipated. For US investors, the current undervaluation signals—pointing to 28% below intrinsic value per DCF models—present a potential entry point in a defensive healthcare sector amid volatile markets.

As of: 26.03.2026

Dr. Elena Vasquez, Senior MedTech Analyst: Becton Dickinson's pivot to streamlined medtech operations positions it for resilient growth in essential medical devices, even as short-term spin-off transitions test investor patience.

Recent Earnings Beat Highlights Execution Strength

Becton Dickinson's latest quarterly results underscore operational resilience. The company delivered revenue growth of 1.6% year over year to $5.25 billion, surpassing analyst forecasts. Adjusted EPS came in at $2.91, beating consensus by $0.10, reflecting stronger-than-expected performance across key markets as stated by CEO Tom Polen. This execution comes at a pivotal time, with the firm issuing FY2026 guidance of $12.35 to $12.65 EPS, signaling confidence in sustained profitability.

Management emphasized productivity gains and innovation focus, particularly in the wake of portfolio restructuring. Return on equity stood at 15.76%, with net margins at 8.01%, metrics that compare favorably within the medical equipment space. For US investors, these figures highlight Becton Dickinson's ability to generate cash flow—latest twelve-month free cash flow reached about $2.60 billion—supporting dividends and strategic initiatives.

The board authorized a $10 million share repurchase program, a move often interpreted as a signal that leadership views shares as undervalued. Coupled with a quarterly dividend of $1.05, annualizing to $4.20 and yielding around 2.7% at current levels on the NYSE, this appeals to income-focused portfolios seeking stability.

Argus Price Target Cut Sparks Valuation Debate

On March 23, 2026, Argus Research lowered its price target on the Becton Dickinson stock to $180 from $230 while maintaining a Buy rating. The adjustment reflects the company's transition following the spin-off of its Biosciences and Diagnostics Solutions business, reshaping it into a pure-play medtech entity. Shares now trade at about 11.5 times forward earnings, well below the 20.4 times average for Argus's MedTech coverage universe.

This move aligns with broader analyst sentiment. Citigroup trimmed its target to $232 from $233 with a Buy, while JPMorgan cut to $175 with Neutral. Conversely, Bank of America raised to $207 (Neutral), Stifel to $215 (Buy), and TD Cowen to $189 (Hold). These adjustments come as the stock opened around $156.92 recently on the NYSE, with a 52-week range of $127.62 to $187.35.

Valuation models add nuance. A two-stage DCF using projected free cash flow to $3.73 billion by 2030 estimates intrinsic value at $219.87 per share, suggesting 28% undervaluation versus the NYSE close of $158.27. The current P/E of 25.65x sits below the industry average of 27.50x and peer group of 31.61x, per fair ratio analysis adjusted for growth and risks.

Strategic Pivot to Pure-Play MedTech Model

Becton Dickinson's transformation centers on shedding non-core units to focus on high-margin medical devices and solutions. CEO Tom Polen highlighted this 'New BD' pivot, emphasizing innovation in areas like vascular access, surgical instruments, and infusion systems. The spin-off streamlines operations, potentially boosting margins through dedicated R&D and productivity measures.

This repositioning addresses prior headwinds, including Alaris pump issues and China market challenges. By concentrating on medtech essentials, the company targets durable demand from hospitals and clinics, less sensitive to economic cycles. US investors benefit from this focus, as domestic healthcare spending remains robust, driven by aging demographics and procedural volumes.

Projected free cash flow growth supports long-term value creation. Analysts forecast steady expansion, with community narratives ranging from optimistic $253 fair value to cautious $183, centering on $197 consensus. This dispersion reflects debates over execution risks but underscores upside potential if the pivot succeeds.

Why US Investors Should Watch BDX Closely Now

For US investors, Becton Dickinson stock offers defensive appeal in healthcare. As a dividend aristocrat with 50+ years of increases, it provides stability amid AI hype and market rotations. The 2.7% yield, backed by strong cash flows, suits balanced portfolios seeking income without excessive volatility.

Domestic exposure dominates, with key products integral to US hospitals. Recent institutional moves—Davenport trimming 4.8% to 614,002 shares worth $119.45 million, yet others like Activest adding positions—signal selective accumulation. Invesco Growth and Income Fund bought 173,396 shares, betting on recovery.

Broader context: the stock's 14.1% 30-day decline on the NYSE contrasts with sector resilience. Undervaluation metrics suggest mean reversion potential, especially if FY2026 guidance holds. US investors gain from regulatory familiarity and proximity to innovation hubs.

Institutional Activity and Insider Signals Mixed

Institutional flows paint a nuanced picture. Davenport & Co reduced its stake by 4.8%, selling 30,699 shares in Q4, yet holds significant exposure. Smaller managers like Imprint Wealth and Cornerstone Planning Group initiated or boosted positions in Q3, indicating entry at lower levels.

Insider activity includes EVP Michael David Garrison selling 1,610 shares in January, typical for personal financial planning. Buyback authorization, though modest at $10 million, reinforces undervaluation views. These patterns suggest institutions position for rebound while trimming near-term risk.

Volume trends show activity, with 2 million shares on March 24 and 71,504 million noted March 25—likely a reporting variance—but indicate liquidity on NYSE. US investors can leverage this for portfolio adjustments.

Risks and Open Questions Ahead

Despite positives, challenges persist. The medtech transition carries execution risks, including integration costs and customer shifts post-spin-off. China headwinds and Alaris remediation linger as drags, potentially pressuring short-term growth.

Analyst forecasts for current-year EPS at $14.43 exceed company FY2026 guidance, highlighting potential conservatism or upside surprise. Broader sector pressures, like reimbursement changes or supply chain issues, could impact margins. Competition in devices remains fierce.

Stock volatility—down 20% since 2018 peaks without full recovery—warrants caution. US investors must weigh undervaluation against macro uncertainties like interest rates affecting healthcare capex. Monitoring Q2 results will clarify trajectory.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.